Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Copaxone (glatiramer acetate) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
• This summary is based on the review of three systematic reviews/meta-analyses. ^[1-4]
• Glatiramer acetate (GA) did not outperform alemtuzumab, mitoxantrone, natalizumab, and fingolimod in reducing relapses or preventing disability worsening within the first 24 months in patients with relapsing-remitting multiple sclerosis (RRMS).
• GA demonstrated a small to moderate positive effect on cognitive test performance in RRMS patients, which was similar to β-interferon but not statistically superior to other disease-modifying treatments (DMTs).
• GA has shown potential neuroprotective effects in neurodegenerative diseases, with some evidence suggesting it mitigates MS-associated cognitive decline, though further large-scale clinical trials are needed to confirm these findings.
• Almost all agents, including GA, exhibited higher withdrawal rates due to adverse events compared to placebo, but specific adverse event rates for GA were not detailed.
• No specific safety concerns or adverse effects of GA were reported in the context of its neuroprotective uses, and safety data specific to GA was not detailed in the reviewed studies.
• There is no population type or subgroup information available in the reviewed studies.